Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-12-15
Based on 1113 first isolates · ED · Cystitis (lower UTI) · 2023-12-17 → 2024-12-15
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 85 % (83 %–87 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (4 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
83 %
n = 86
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
85 %
90 %
n = 86
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
82 %
76 %
n = 86
ciprofloxacin CIP
trend · Escherichia coli
81 %
74 %
n = 86
ceftriaxone CRO
trend · Escherichia coli
80 %
73 %
n = 86
mecillinam MEC
trend · Escherichia coli lower UTI only
80 %
78 %
n = 86
trimethoprim TMP
trend · Escherichia coli lower UTI only
77 %
76 %
n = 86
74 %
70 %
n = 86
51 %
51 %
n = 86
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
11 %
14 %
n = 86
4 %
3 %
n = 86
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
5 %
n = 86

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
8 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
4 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.